Veradermics, Inc (MANE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Veradermics reported revenue of $0. Net income was -$70.0M, or -$111.91 per diluted share. Operating activities generated -$71.6M of cash, leaving -$71.6M of free cash flow. At fiscal year end, Veradermics held $152.6M in total assets against $9.2M in total liabilities, including $21.8M of cash and equivalents.
Open the full interactive Veradermics financials → Quarterly statements, key ratios, valuation history and price charts.
Veradermics Key Stats
| Share Price | $116.26 |
|---|---|
| Market Cap | $4.70B |
| 52-Week Range | $37.03 – $130.90 |
| Shares Outstanding | 40.4 million (basic, 2026 Q2) |
Veradermics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$72.3M |
| Pre-Tax Income | -$70.0M |
| Income Tax | $0 |
| Net Income | -$70.0M |
| Diluted EPS | -$111.91 |
Veradermics Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | -$27.2M | -$23.5M |
| Diluted EPS | -$1.32 | -$0.58 |
Veradermics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $21.8M |
| Current Assets | $152.5M |
| Total Assets | $152.6M |
| Current Liabilities | $9.2M |
| Total Liabilities | $9.2M |
| Shareholders' Equity | -$121.0M |
Veradermics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$71.6M |
| Cash From Investing | -$118.9M |
| Cash From Financing | $159.1M |
| Free Cash Flow | -$71.6M |
Figures from Veradermics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Veradermics financials page for every line item.
Veradermics Company Profile
| Ticker | MANE |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001827635 |
Frequently Asked Questions
What was Veradermics' revenue in fiscal 2025?
Veradermics (MANE) reported revenue of $0 for fiscal 2025.
What was Veradermics' net income in fiscal 2025?
Veradermics reported net income of -$70.0M for fiscal 2025.
What was Veradermics' earnings per share (EPS) in fiscal 2025?
Veradermics' diluted EPS was -$111.91 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Veradermics generate in fiscal 2025?
Veradermics generated -$71.6M of free cash flow in fiscal 2025.
What was Veradermics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Veradermics reported revenue of $0.
How many shares of Veradermics are outstanding?
Veradermics reported a weighted average of 40.4 million basic shares outstanding in 2026 Q2.
What is Veradermics' market cap?
Based on its latest closing price, Veradermics (MANE) has a market capitalization of about $4.70B.
When does Veradermics' fiscal year end?
Veradermics' fiscal year end, as registered with the SEC, is December 31.
Where is Veradermics headquartered?
Veradermics lists its business address in New Haven, Connecticut in its SEC filings.